Source: Invest in Russia, 26.12.2017
US biotech major Amgen (Nasdaq: AMGN) has announced its plans to establish the production of its antitumor drug blinatumomab at the facilities of Russian Pharmstandard next year, according to the companies, reports The Pharma Letter’s local correspondent.
To date, they have already reached an agreement for the establishment of a full cycle production of blinatumomab.
Under the terms of the agreement, Amgen will transfer production technologies to Pharmstandard, while the Russian company will promote the product in the local market.
Planned production volumes are 50,000 bottles' per year. Amgen will remain an owner of the registration certificate of the drug.
Localization is planned at the Pharmstandard plant in Ufa in two stages. Next year, a secondary package of the drug will be organized. At the same time, starting from 2021 a full-scale production of the drug will be launched.
The value of investments is not disclosed. Amgen's general director in Russia Oleg Paroshin expects the payback period of the project will be about seven years.